VVT raised $1 million to ramp up manufacturing of its Sclerosafe varicose vein device, which is now seeing successful insurance/Medicaid reimbursement across the USA. This should, which should further accelerate the company’s adoption by distributors around the world. Heavyweight Michal Tisser participated in the offering. VVT continues to complete varicose vein treatments - nearly 3,000 now - without any reported pain or complications, which is a game-changer. Full article here: https://www.newswire.ca/news-releases/vvt-med-closes-1-065-664-first-tranche-of-private-placement-of-units-846835831.html
